靶向传播恶性疟原虫和间日疟原虫的组合疫苗的评估
本研究利用DNA疫苗平台在小鼠中评估基于P25和P48/45的单价及组合疫苗的免疫原性,以拓宽针对恶性疟原虫和间日疟原虫的疫苗特异性。单价和组合DNA疫苗均诱导了强效抗体应答,组合免疫未削弱特异性抗体应答。抗Pvs25和抗Pfs25/抗Pfs48/45 IgG显示出浓度或剂量依赖的传播阻断活性,但Pvs48/45 DNA疫苗诱导的抗体在DMFA中无效,需进一步优化疫苗构建体。
要点
- 单价和组合DNA疫苗在小鼠中均诱导强效抗体应答,组合未削弱特异性应答。
- 抗Pvs25和抗Pfs25 IgG显示浓度依赖的传播阻断活性。
- Pvs48/45 DNA疫苗诱导的抗体在DMFA中无效,需优化构建体。
核心结论
- 这些研究为组合多种抗原以同时靶向恶性疟原虫和间日疟原虫引起的传播提供了依据。
- Pvs48/45 DNA疫苗诱导的抗体在DMFA中无效,需进一步优化疫苗构建体。
研究设计与样本
- 使用DNA疫苗平台,在小鼠中通过体内电穿孔评估编码Pvs25、Pfs25、Pvs48/45和Pfs48/45的单价DNA疫苗及多种组合疫苗的免疫原性。
主要发现
- 单价和组合DNA疫苗在小鼠中均诱导了强效抗体应答,组合疫苗与单价疫苗相比特异性抗体应答未受削弱。
- 来自单价和组合组的抗Pvs25 IgG在直接膜喂养试验(DMFA)中显示浓度依赖的传播减少活性,该试验使用巴西间日疟原虫感染供者血液。
- 抗Pvs25 IgG在使用Pvs25转基因伯氏疟原虫的离体膜喂养试验(MFA)中独立显示传播减少活性。
- 用Pfs25和Pfs48/45 DNA疫苗单独或各种组合免疫的小鼠的抗Pfs25和抗Pfs48/45 IgG,在使用培养来源恶性疟原虫配子体的标准膜喂养试验(SMFA)中显示抗体剂量依赖的传播减少活性。
- Pvs48/45 DNA疫苗诱导的抗体在DMFA中无效,竞争ELISA显示可能诱导传播阻断和传播增强抗体。
局限性
- Pvs48/45 DNA疫苗诱导的抗体在DMFA中无效,需进一步优化疫苗构建体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transmission-blocking vaccines interrupting malaria transmission within mosquitoes represent an ideal public health tool to eliminate malaria at the population level. Plasmodium falciparum and P. vivax account for more than 90% of the global malaria burden, co-endemic in many regions of the world. P25 and P48/45 are two leading candidates for both species and have shown promising transmission-blocking activity in preclinical and clinical studies. However, neither of these target antigens as individual vaccines has induced complete transmission inhibition in mosquitoes. In this study, we assessed immunogenicity of combination vaccines based on P25 and P48/45 using a DNA vaccine platform to broaden vaccine specificity against P. falciparum and P. vivax. Individual DNA vaccines encoding Pvs25, Pfs25, Pvs48/45 and Pfs48/45, as well as various combinations including (Pvs25 + Pvs48/45), (Pfs25 + Pfs48/45), (Pvs25 + Pfs25), and (Pvs48/45 + Pfs48/45), were evaluated in mice using in vivo electroporation. Potent antibody responses were induced in mice immunized with individual and combination DNA vaccines, and specific antibody responses were not compromised when combinations of DNA vaccines were evaluated against individual DNA vaccines. The anti-Pvs25 IgG from individual and combination groups revealed concentration-dependent transmission-reducing activity (TRA) in direct membrane feeding assays (DMFA) using blood from P. vivax-infected donors in Brazil and independently in ex vivo MFA using Pvs25-transgenic P. berghei. Similarly, anti-Pfs25 and anti-Pfs48/45 IgGs from mice immunized with Pfs25 and Pfs48/45 DNA vaccines individually and in various combinations revealed antibody dose-dependent TRA in standard membrane feeding assays (SMFA) using culture-derived P. falciparum gametocytes. However, antibodies induced by immunization with Pvs48/45 DNA vaccines were ineffective in DMFA and require further vaccine construct optimization, considering the possibility of induction of both transmission-blocking and transmission-enhancing antibodies revealed by competition ELISA. These studies provide a rationale for combining multiple antigens to simultaneously target transmission of malaria caused by P. falciparum and P. vivax.
引用
- Cao Y, Hayashi CTH, Araujo MDS, et al. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax. Vaccine. 2024. PMID: 39033079. doi:10.1016/j.vaccine.2024.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。